Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRMD | CORMEDIX INC | $876.97M | $82.55M | $17.67M | $17.18M | $0.26 | N/A | 235.70% | N/A | N/A | |||
| TGTX | TG THERAPEUTICS INC | $4.46B | $454.07M | $97.52M | $60.46M | $0.41 | 30.96% | 395.51% | -39.71% | N/A | |||
| CORT | CORCEPT THERAPEUTICS INC | $7.56B | $716.08M | $102.16M | $131.98M | $1.26 | 25.71% | 15.31% | 3.28% | 4.94% | |||
| GYRE | GYRE THERAPEUTICS INC | $783.99M | $102.19M | $9.86M | $4.17M | $0.04 | -8.42% | 41.49% | N/A | N/A | 2025-08-19 | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.47B | $529.33M | $19.04M | $4.79M | $0.06 | 56.18% | N/A | N/A | N/A | |||
| KRYS | KRYSTAL BIOTECH INC | $4.35B | $359.21M | $175.01M | $146.73M | $5.11 | 116.09% | N/A | 35.54% | N/A | |||
| HALO | HALOZYME THERAPEUTICS INC | $7.87B | $1.18B | $791.84M | $557.28M | $4.48 | 34.97% | 45.55% | 71.65% | N/A | |||
| ARGX | ARGENX SE | $39.91B | $1.92M | $811.30M | $1.51B | $25.02 | -94.62% | -50.87% | N/A | N/A | |||
| RPRX | ROYALTY PHARMA PLC | $21.20B | $2.31B | $1.29B | $1.02B | $2.31 | 3.02% | 3.58% | 52.98% | N/A | |||
| INVA | INNOVIVA INC | $1.32B | $370.23M | $125.47M | $38.65M | $0.61 | 12.02% | 4.34% | -72.89% | -22.98% | |||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.62B | $260.11M | $86.50M | $60.64M | $0.44 | 25.59% | 282.43% | N/A | N/A | |||
| VCEL | VERICEL CORP | $1.83B | $249.12M | $22.06M | $7.11M | $0.14 | 16.13% | 16.40% | 1,300.00% | 47.58% | |||
| EXEL | EXELIXIS INC | $10.31B | $2.23B | $831.10M | $602.30M | $2.15 | 10.73% | 17.44% | 83.76% | 18.50% | |||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.12B | $772.53M | $265.05M | $180.90M | $3.16 | 17.74% | 64.65% | 59.60% | N/A | |||
| INCY | INCYTE CORP | $16.97B | $4.58B | $1.36B | $870.87M | $4.42 | 18.87% | 13.94% | 1,063.16% | N/A | |||
| ADMA | ADMA BIOLOGICS INC | $4.05B | $474.17M | $163.11M | $208.93M | $0.88 | 43.58% | 66.33% | 486.67% | N/A | |||
| MNKD | MANNKIND CORP | $1.14B | $301.74M | $79.10M | $32.80M | $0.11 | 21.48% | 37.26% | 120.00% | N/A | |||
| ATRA | ATARA BIOTHERAPEUTICS INC | $86.31M | $188.67M | $24.86M | $5.80M | $0.73 | 202.41% | N/A | N/A | N/A | |||
| MDXG | MIMEDX GROUP INC | $1.05B | $363.77M | $54.38M | $32.17M | $0.22 | 6.85% | 5.33% | -65.63% | N/A | |||
| TECH | BIO-TECHNE CORP | $8.40B | $1.21B | $289.57M | $131.67M | $0.83 | 4.72% | 9.88% | -34.65% | -7.46% | |||
| VCYT | VERACYTE INC | $2.37B | $463.39M | $63.03M | $33.05M | $0.43 | 23.42% | 30.60% | N/A | N/A | |||
| NVO | NOVO NORDISK A S | $234.01B | $48.66B | $24.46B | $17.33B | $3.90 | 32.31% | 20.73% | 35.66% | 24.15% | |||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.05B | $3.06B | $934.37M | $657.24M | $3.44 | 18.36% | 10.65% | 154.81% | 37.89% | |||
| NAGE | NIAGEN BIOSCIENCE INC | $799.12M | $116.30M | $19.78M | $17.73M | $0.23 | 35.89% | 16.25% | N/A | N/A | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.48B | $558.50M | $310.08M | $208.67M | $1.73 | 28.55% | 36.06% | 193.22% | 34.03% | |||
| GMAB | GENMAB A | $14.95B | $3.32B | $1.82B | $1.25B | $1.97 | 22.50% | 18.03% | 62.49% | 9.89% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $100.71B | $11.42B | $4.59B | $3.64B | $14.12 | 10.46% | 16.15% | N/A | 11.98% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.